Peptide Record

Semaglutide · full corpus

Explore

Every evidence record, mention, review and regulatory filing collected for Semaglutide, in one list. Each row links to the original. Nothing here is summarised for you — this is the corpus, source tag by source tag.

2,935 records · ordered by source hierarchy — human trials first, vendor material last

Corpus records for Semaglutide
SourceKindRecordAttributionDetailDate
HUMAN-TRIALevidenceComparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.SemaglutideWeight & fat loss · human-observational2026-12-01
HUMAN-TRIALevidenceCost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.WegovyWeight & fat loss · human-observational2026-12-01
HUMAN-TRIALevidenceEvaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double-Blind Phase II Trial.SemaglutideGlycemic control · human-rct2026-08-01
HUMAN-TRIALevidenceThe impact of automated insulin delivery on glucose management in people with diabetes and advanced chronic kidney disease.SemaglutideGlycemic control · human-rct2026-08-01
HUMAN-TRIALevidenceMulti-Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial.SemaglutideGlycemic control · human-rct2026-08-01
HUMAN-TRIALevidenceEfficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.SemaglutideGlycemic control · human-rct · n = 1892026-08-01
HUMAN-TRIALevidenceAssociation of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study.SemaglutideGlycemic control · human-observational2026-08-01
HUMAN-TRIALevidenceImplementation of the IWQOL-Lite-CT in Observational Research: Comparison of Baseline Scores With a Clinical Trial Population and Psychometric Evaluation.SemaglutideWeight & fat loss · human-observational2026-08-01
HUMAN-TRIALevidenceCagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.SemaglutideGlycemic control · human-rct2026-08-01
HUMAN-TRIALevidenceSemaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes.SemaglutideWeight & fat loss · human-rct2026-08-01
HUMAN-TRIALevidenceSemaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study.OzempicGlycemic control · human-rct2026-08-01
HUMAN-TRIALevidenceGlucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy.SemaglutideGlycemic control · human-observational · n = 1732162026-08-01
HUMAN-TRIALevidenceCagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.SemaglutideGlycemic control · human-rct2026-07-04
HUMAN-TRIALevidenceDifferential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes.SemaglutideGlycemic control · human-observational2026-07-01
HUMAN-TRIALevidenceSemaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial.SemaglutideMood & anxiety · human-rct · n = 722026-07-01
HUMAN-TRIALevidenceOrforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.SemaglutideWeight & fat loss · human-rct2026-07-01
HUMAN-TRIALevidenceShort-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease.SemaglutideGlycemic control · human-rct2026-07-01
HUMAN-TRIALevidenceEffects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial.SemaglutideGlycemic control · human-rct2026-07-01
HUMAN-TRIALevidenceSemaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.SemaglutideWeight & fat loss · human-rct2026-07-01
HUMAN-TRIALevidenceRelationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis.SemaglutideWeight & fat loss · human-rct2026-07-01
HUMAN-TRIALevidenceSemaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.SemaglutideGlycemic control · human-rct2026-07-01
HUMAN-TRIALevidenceCardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study.SemaglutideGlycemic control · human-observational2026-07-01
HUMAN-TRIALevidenceEarly Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study.SemaglutideWeight & fat loss · human-observational2026-07-01
HUMAN-TRIALevidenceEffects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial.SemaglutideWeight & fat loss · human-rct2026-07-01
HUMAN-TRIALevidenceRenal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.SemaglutideGlycemic control · human-rct2026-07-01
HUMAN-TRIALevidenceIschemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk.OzempicGlycemic control · human-observational2026-06-22
HUMAN-TRIALevidenceElecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.SemaglutideGlycemic control · human-rct2026-06-20
HUMAN-TRIALevidenceKidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses.SemaglutideGlycemic control · human-rct2026-06-02
HUMAN-TRIALevidenceEmulated Effects of Glucagon-Like Peptide 1 Receptor Agonist Therapy in the General Population.Semaglutidehuman-rct2026-06-02
HUMAN-TRIALevidenceCombining GLP-1 Receptor Agonists and Health-Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real-World Single-Center Study.SemaglutideWeight & fat loss · human-observational2026-06-01
HUMAN-TRIALevidenceSEMASEARCH Study Design: Real-World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials.SemaglutideWeight & fat loss · human-observational2026-06-01
HUMAN-TRIALevidencePreoperative GLP-1 Receptor Agonists and Thromboinflammatory Markers in Patients Undergoing Abdominoplasty: A Prospective Monocentric Study.SemaglutideWeight & fat loss · human-observational2026-06-01
HUMAN-TRIALevidenceReal-world weight loss with injectable semaglutide vs dulaglutide for diabetes.OzempicGlycemic control · human-observational · n = 1202026-06-01
HUMAN-TRIALevidenceReal-world impact of oral semaglutide on inflammatory markers in patients at high cardiovascular risk.SemaglutideGlycemic control · human-observational2026-06-01
HUMAN-TRIALevidencePatient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes.SemaglutideGlycemic control · human-observational · n = 2302026-06-01
HUMAN-TRIALevidenceOral semaglutide reduces diabetes-related distress in adults with type 2 diabetes mellitus switching from DPP-4 inhibitors. The DOORS prospective real-world Italian study.SemaglutideGlycemic control · human-observational2026-06-01
HUMAN-TRIALevidenceEfficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development Approach.WegovyWeight & fat loss · human-rct2026-06-01
HUMAN-TRIALevidenceEfficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.Semaglutidehuman-rct2026-06-01
HUMAN-TRIALevidenceReal-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system.SemaglutideWeight & fat loss · human-observational2026-06-01
HUMAN-TRIALevidenceEfficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.SemaglutideCognition & memory · human-rct · n = 38082026-05-30
HUMAN-TRIALevidenceSemaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy.SemaglutideLongevity & cellular aging · human-rct · n = 842026-05-19
HUMAN-TRIALevidenceGlucagon-like peptide-1 receptor agonists in patients with heart failure with reduced ejection fraction.SemaglutideLipid & cardiovascular markers · human-observational · n = 1270212026-05-05
HUMAN-TRIALevidenceOnce-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.Semaglutidehuman-rct2026-05-02
HUMAN-TRIALevidenceTirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study.SemaglutideCognition & memory · human-observational2026-05-01
HUMAN-TRIALevidenceSemaglutide Effects on Insulin Sensitivity and beta-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly.SemaglutideGlycemic control · human-rct2026-05-01
HUMAN-TRIALevidenceComparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study.SemaglutideGlycemic control · human-observational2026-05-01
HUMAN-TRIALevidenceOral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.SemaglutideGlycemic control · human-rct2026-05-01
HUMAN-TRIALevidenceMuscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study.Semaglutidehuman-observational2026-05-01
HUMAN-TRIALevidenceDose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.SemaglutideGlycemic control · human-rct2026-05-01
HUMAN-TRIALevidenceSemaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.Semaglutidehuman-rct2026-05-01